Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure …
…, H Wandt, H Steinhauer, S Martin… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to
moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to …
moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to …
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
…, A Kerkhoff, M Ahlborn, TV Halbsguth, S Martin… - The Lancet …, 2021 - thelancet.com
Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
Emotional context during encoding of neutral items modulates brain activation not only during encoding but also during recognition
S Erk, S Martin, H Walter - Neuroimage, 2005 - Elsevier
In general, encoding of neutral material includes the context in which the respective material
is learned. The effect of emotional context on successfully encoded neutral material has …
is learned. The effect of emotional context on successfully encoded neutral material has …
[PDF][PDF] Mutations in ACTL6B cause neurodevelopmental deficits and epilepsy and lead to loss of dendrites in human neurons
…, SG Mehta, D Huhle, R Abou Jamra, S Martin… - The American Journal of …, 2019 - cell.com
We identified individuals with variations in ACTL6B, a component of the chromatin remodeling
machinery including the BAF complex. Ten individuals harbored bi-allelic mutations and …
machinery including the BAF complex. Ten individuals harbored bi-allelic mutations and …
[PDF][PDF] De novo variants in GRIA4 lead to intellectual disability with or without seizures and gait abnormalities
S Martin, A Chamberlin, DN Shinde, M Hempel… - The American Journal of …, 2017 - cell.com
Using trio whole-exome sequencing, we have identified de novo heterozygous pathogenic
variants in GRIA4 in five unrelated individuals with intellectual disability and other symptoms. …
variants in GRIA4 in five unrelated individuals with intellectual disability and other symptoms. …
Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis
…, T Schroeder, D Bunjes, J Tischer, S Martin… - Clinical Cancer …, 2022 - AACR
Purpose: We evaluated outcomes of unrelated transplantation for primary refractory/relapsed
(ref/rel) acute myeloid leukemia (AML), comparing two cohorts according to the year of …
(ref/rel) acute myeloid leukemia (AML), comparing two cohorts according to the year of …
Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survival in older (> 55 years) patients with de novo B …
…, A Rank, M Haenel, B Spriewald, M Hanoun, S Martin… - Blood, 2022 - ashpublications.org
Introduction: Acute lymphoblastic leukemia (ALL) represents approx. 5% of all newly
diagnosed leukemias in patients (pts) between 55 and 70 years of age. Incorporation of novel …
diagnosed leukemias in patients (pts) between 55 and 70 years of age. Incorporation of novel …
[HTML][HTML] First results of the risk-adapted, MRD-stratified GMALL trial 08/2013 in 705 adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL/LBL)
…, K Wendelin, M Hanoun, R Wäsch, J Beck, S Martin… - Blood, 2021 - Elsevier
In the past decade outcome of adult ALL was improved significantly using pediatric-based
chemotherapy in combination with risk-adapted stem cell transplantation (SCT) and targeted …
chemotherapy in combination with risk-adapted stem cell transplantation (SCT) and targeted …
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
…, N Basara, C Koenecke, S Martin… - Leukemia & …, 2022 - Taylor & Francis
In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell
transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the …
transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the …
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid …
…, G Borthakur, A Frankel, HA Horst, S Martin… - … Myeloma and Leukemia, 2011 - Elsevier
Background XIAP (X-linked inhibitor of apoptosis protein) is an inhibitor of caspases 3 and 9
that is overexpressed in acute myeloid leukemia (AML) and may contribute to …
that is overexpressed in acute myeloid leukemia (AML) and may contribute to …